Abstract 669P
Background
Tumor-targeted drug delivery technologies are urgently needed to overcome conventional chemotherapy’s lack of tumor selectivity. Alphalex conjugates, which contain a pH-low insertion peptide (pHLIP), a linker and a payload are designed to overcome this lack of selectivity. Alphalex PDCs target tumors in an antigen-independent manner. At pH 7.4, the peptide is unstructured. In the low pH tumor microenvironment the peptide forms an alpha helix and inserts directionally into the tumor cell membrane delivering the linker and payload. For CBX-12 the payload is exatecan.
Methods
In this Phase 1 trial, cohorts of pts were treated with escalating doses of CBX-12 in a 3 + 3 design. The primary objectives are safety, tolerability and to determine the MTD/RP2D. Secondary and exploratory objectives include evaluation of plasma PK of CBX-12 and exatecan, anti-tumor activity per RECIST v1.1, and measurement of anti-drug antibodies.
Results
Enrollment is complete with 69 pts having been treated on study. The most frequent treatment-related AEs (TRAEs) were anaemia (53.6%), leukopenia (42.0%), neutropenia (40.6%), nausea (39.1%), and fatigue (36.2%). The most frequent Gr3/4 TRAEs were neutropenia, (27.5%), anaemia (24.6%), leukopenia (21.7%), and thrombocytopenia (13.0%). No ILD or ophthalmic toxicity was reported. There were 5 confirmed responses in ovarian (2), breast (2), and colorectal cancer (1). Evidence of activity was also seen in NSCLC, cholangiocarcinoma, and thymic cancer. Of 12 patients with ovarian cancer there was one confirmed complete response, one confirmed partial response (PR) and tw0 unconfirmed PRs. 8 of 12 saw clinical benefit. The RP2D was established as 125mg/m2 every 21 days.
Conclusions
Tumor targeting facilitated by this pH sensitive peptide made possible an improved safety profile despite the administration of a 5-fold increase in the dose of exatecan compared to unconjugated exatecan. The dose limiting toxicity is myelosuppression. CBX-12 demonstrated broad activity with 5 confirmed responses in three malignancies. A randomized Phase 2 study in platinum resistant ovarian cancer is underway comparing two doses on the once every 21 day schedule.
Clinical trial identification
NCT04902872.
Editorial acknowledgement
Legal entity responsible for the study
Cybrexa Inc.
Funding
Cybrexa Inc.
Disclosure
F. Meric-Bernstam: Financial Interests, Personal and Institutional, Funding: Cybrexa, Inc. P. Pearson: Financial Interests, Personal, Financially compensated role, Consultant: Cybrexa, Inc. M.N. Needle: Financial Interests, Personal, Full or part-time Employment: Cybrexa, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01